US2005233947A1PendingUtilityA1

Combinations of chromium or vanadium with antidiabetics

62
Individually held — no corporate assignee on recordPriority: Sep 17, 1998Filed: Mar 23, 2005Published: Oct 20, 2005
Est. expirySep 17, 2018(expired)· nominal 20-yr term from priority
Inventors:Stuart FineKevin Kinsella
A61K 31/175A61K 31/426A61K 31/555A61P 3/08A61K 45/06A61P 3/10A61K 31/155A61K 33/24
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.

Claims

exact text as granted — not AI-modified
1 - 96 . (canceled)  
   
   
       97 . A composition comprising synergistic effective amounts of an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a meglitinide, and wherein components of said composition synergistically reduce the HbA1c levels of a patient by at least about 10% after treatment for a period of at least about thirty days with said composition as compared to treatment with said anti-diabetic agent alone.  
   
   
       98 . The composition according to  claim 97 , wherein said meglitinide is repaglinide.  
   
   
       99 . The composition of  claim 97 , wherein said reduction in said Hb1Ac level is at least about 50%.  
   
   
       100 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises one or more of chromium picolinate or chromium polynicotinate.  
   
   
       101 . The composition according to  claim 100 , wherein the bioavailable source of chromium is chromium picolinate and wherein the amount of chromium picolinate is from about 30 μg up to about 1000 μg, per dose.  
   
   
       102 . The composition according to  claim 100 , wherein the bioavailable source of chromium is chromium polynicotinate and wherein the amount of chromium polynicotinate is from about 30 μg up to about 5000 μg, per dose.  
   
   
       103 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises no less than about 200 micrograms of elemental chromium.  
   
   
       104 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises no less than about 100 micrograms of elemental chromium.  
   
   
       105 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises no less than about 5 micrograms of elemental chromium.  
   
   
       106 . The composition of  claim 97 , wherein said bioavailable source of vanadium is vanadyl sulfate.  
   
   
       107 . The composition of  claim 106 , wherein the amount of vanadyl sulfate is in the range of about 20 mg up to about 100 mg, per dose.  
   
   
       108 . The composition of  claim 97 , wherein said bioavailable source of vanadium comprises more than about 10 mg elemental vanadium.  
   
   
       109 . The composition of  claim 97 , wherein said amount of said bioavailable source of vanadium comprises no less than 5 mg of elemental vanadium.  
   
   
       110 . The composition according to  claim 100 , wherein said meglitinide is repaglinide.  
   
   
       111 . The composition according to  claim 106 , wherein said meglitinide is repaglinide.  
   
   
       112 . A method for improving glucose metabolism, comprising treating a patient for at least about a thirty day period by administering a pharmaceutical composition comprising synergistic effective amounts of an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a meglitinide, and wherein said components of said composition synergistically reduce the HbA1c level of said patient by at least about 10% after such treatment as compared to treatment with said anti-diabetic agent alone.  
   
   
       113 . The method of  claim 112 , wherein said bioavailable source of chromium comprises no less than about 200 micrograms elemental chromium when said composition is administered on a daily basis.  
   
   
       114 . The method of  claim 112 , wherein said bioavailable source of chromium comprises no less than about 5 micrograms of elemental chromium when said composition is administered on a daily basis.  
   
   
       115 . The method of  claim 112 , wherein said bioavailable source of chromium comprises one or more of chromium picolinate or chromium polynicotinate.  
   
   
       116 . The method of  claim 112 , wherein said bioavailable source of vanadium comprises at least about 10 mg elemental vanadium when said composition is administered on a daily basis.  
   
   
       117 . The method of  claim 112 , wherein said bioavailable source of vanadium is vanadyl sulfate.  
   
   
       118 . The method of  claim 112 , wherein said amount of said bioavailable source of vanadium comprises no less than 5 mg of elemental vanadium when said composition is administered on a daily basis.  
   
   
       119 . The method of  claim 112 , wherein said meglitinide is repaglinide.  
   
   
       120 . The method of  claim 112 , wherein said pharmaceutical composition further comprises a physiologically acceptable carrier.  
   
   
       121 . The method of  claim 112 , wherein said method further comprises monitoring said subject's HbA1c levels.  
   
   
       122 . The method of  claim 112 , wherein said reduction in said Hb1Ac level is at least about 50%.

Join the waitlist — get patent alerts

Track US2005233947A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.